Inflamatory Diseases

CV6 Therapeutics is building a pipeline of therapies designed to improve the effectiveness of cornerstone treatments in cancer and inflammatory diseases.

block: text

Our lead clinical asset, CV6-168, is engineered to work in combination with widely used therapies, enhancing their impact without adding toxicity. Additional programs extend this strategy into new disease areas.

block: images

block: programs-phases

CV6-1271

CV6-1271 is a lead preclinical candidate for inflammatory diseases, including rheumatoid arthritis.

Early studies demonstrate activity in disease models, supporting further development toward clinical evaluation.

CV6-1271: Current pHase

Preclinical

block: quotes

“”

Prof. Ruth Plummer, MD

If CV6-168 performs as expected, it could fundamentally change how we use 5-FU in cancer treatment.

block: card-block

Lorem ipsum dolor sit amet consectetur. In consectetur sollicitudin nibh elit iaculis mauris neque suspendisse. Congue suscipit elementum dolor eros. In sagittis.

Programs